ProShares Ultra NASDAQ Biotechnology
24 hedge funds and large institutions have $3.62M invested in ProShares Ultra NASDAQ Biotechnology in 2024 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 4 closing their positions.
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
23% more call options, than puts
Call options by funds: $537K | Put options by funds: $436K
14% more funds holding
Funds holding: 21 → 24 (+3)
1.37% less ownership
Funds ownership: 7.28% → 5.91% (-1.4%)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
44% less capital invested
Capital invested by funds: $6.5M → $3.62M (-$2.88M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$231K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$75K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$34.8K |
| 4 |
LWANC
Laurel Wealth Advisors (North Carolina)
Charlotte,
North Carolina
|
+$17.8K |
| 5 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$14.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IMC Chicago
Chicago,
Illinois
|
-$1.46M |
| 2 |
WWM
Westwood Wealth Management
Los Angeles,
California
|
-$356K |
| 3 |
Jane Street
New York
|
-$306K |
| 4 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
-$166K |
| 5 |
Morgan Stanley
New York
|
-$36.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Jane Street
New York
| – | -$306K | -4,803 | Closed |
|
27
Osaic Holdings
Scottsdale,
Arizona
| – | -$19.1K | -300 | Closed |
|
28
CIBC Private Wealth Group
Atlanta,
Georgia
| – | -$3.83K | -60 | Closed |
|
BIB Hedge Fund Activity: Q4 2024 in Review
24 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q4 2024, worth a combined $3.62M — down 44% from $6.5M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new BIB positions and 4 closed out — a net gain of 3 holders — while 4 added to existing stakes and 5 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $231K. The largest seller was IMC Chicago, exiting entirely with an estimated $1.46M sold.
- 24 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q4 2024, up from 21 in Q3 2024.
- Funds reported $3.62M of ProShares Ultra NASDAQ Biotechnology stock for Q4 2024, down 44% quarter-over-quarter.
- 7 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q4 2024 and 4 closed out, a net change of +3 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q4 2024 was Citadel Advisors, an estimated $231K added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q4 2024 was IMC Chicago, an estimated $1.46M sold.
Based on aggregated 13F filings for Q4 2024.